Mainstay of treatment for CIPN is largely supportive, whereas PD-1 inhibitor-associated peripheral neuropathies frequently also employ immunosuppression with agents like steroids or intravenous immunoglobulin (IVIG) in their management [6]. The gene discussed is PDCD1; the disease is peripheral neuropathy.